Figure 3 | Scientific Reports

Figure 3

From: PTENP1-AS contributes to BRAF inhibitor resistance and is associated with adverse clinical outcome in stage III melanoma

Figure 3

Characterization of the PTEN promoter in A375 and A375PR1 cell lines. (a) qRTPCR measuring PTEN promoter CpG methylation, as determined by the remaining (unmethylated) DNA upon treatment with the methyl-cytosine-specific restriction enzyme McrBc (n = 3). (b–c) ChIP followed by qRTPCR analysis measuring the levels of (b) EZH2 and (c) H3K27me3 at the PTEN promoter in A375 and A375PR1 cell lines (n = 3). (d–e) qRTPCR measuring baseline expression levels of (d) DNMT3A and (e) EZH2 in A375 and A375PR1 cell lines (n = 3). (f–g) qRTPCR measuring the expression levels of PTEN following siRNA induced knockdown of (f) DNMT3A and (g) EZH2 in A375 and A375PR1 cell lines (n > 3). (h) qRTPCR measuring the expression levels of PTEN following simultaneous siRNA-induced knockdown of EZH2 and DNMT3A in A375 and A375PR1 cell lines (n = 3). (a–h; p-values represent a two-tailed student’s t-test).

Back to article page